Reading STAA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track STAA free→Reading STAA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track STAA free→NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-06-12
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is neutral. Earnings quality cannot be assessed since the company is unprofitable. Management's recent track record has been steady. Risk is high, and the sector backdrop is a headwind. Peer multiples imply a price about 145% below where it trades (it looks expensive on this basis); the read is expensive, growth-justified. If STAA cuts guidance on the next call, that could be negative.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 5 valuation methods, at three horizons. Current price $28.37. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $28 the market pays 63× p/e — above the 23× p/e peer median but in line with its own 66× history. That premium reflects a durable franchise our peer-anchored $14 fair value understates; treat the 'expensive vs peers' read with low confidence. Analysts: $18–$40. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 107% near-term growth, well above our forecast of about 11%. This describes what's priced in, not a forecast of the move.
Flags: expensive valuation, a turbulent sector regime (Heating).
For similar setups historically (n=2,301): about 43% saw a 20%+ drawdown, and roughly 77% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 2.39x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates.
1 material management or governance event in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.20 → $0.23 (+15.0% / 30d). 4 raised, 0 cut, 8 covering analysts.
1 upgrade, 0 downgrades / 30d, 6 maintained. 27% of analysts rate Buy.
0 positive, 0 negative / 30d.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$194.
How much price usually moves either way.
On a bad day, this stock has moved -$550.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $4,365.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-12
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Higher operating income means better cost management. This helps the company make more money.
Confirms:Operating income goes up compared to last quarter.
Disproves:Operating income goes down or stays the same compared to last quarter.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for STAA yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 8, 2026, the Compensation Committee (the “Committee”) of the Board of Directors of STAAR Surgical Company (the “Company”) approved an increase to the annual base salary of Deborah Andrews, the Company's Interim Co-Chief Executive Officer and Chief Financial Officer from $512,000 to $575,000. In addition, the Committee approved an increase i…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$18.00 – $40.00 (median $31.00) · 7 analysts · as of 2026-05-14
Looks more expensive than peers.
Around its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Equipment.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
STAA STAAR Surgical Company | Above typical Show detailsSector percentile: 72 of 100 | expensive | high |
ABT Abbott Laboratories | Above typical Show detailsSector percentile: 93 of 100 | inexpensive | moderate |
ISRG Intuitive Surgical | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
SYK Stryker Corporation | Typical Show detailsSector percentile: 67 of 100 | fair | moderate |
MDT Medtronic | Above typical Show detailsSector percentile: 89 of 100 | fair | moderate |
Not investment advice. As of 2026-06-12.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-12.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on increasing revenue growth through market share gains and higher ASPs.
Enhance operating income through cost management and efficiency improvements.
Strive to achieve positive net income through revenue growth and cost control.
Why it matters: Positive net income shows a big gain in financial performance. This is a good sign.
Confirms:Net income reported as positive for the quarter.
Disproves:Net income remains negative for the quarter.
Why it matters: A drop in revenue growth signals a potential slowdown in the company's momentum. This could affect investor confidence.
Confirms:Q2 revenue growth reported below 10% year over year.
Disproves:Q2 revenue growth remains at or above 10% year over year.
Results of Operations and Financial Condition. On May 13, 2026, STAAR Surgical Company (the “Company”) published a press release reporting its financial results for the quarter ended April 3, 2026, a copy of which is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.